



Irish College of
Ophthalmologists
Eye Doctors of Ireland
Protecting your Vision

Celebrating 25 Years

Protecting Eye Health in Ireland

Annual Conference

2016

**THE EUROPE HOTEL, KILLARNEY,
CO KERRY**

May 18th – 20th 2016

SPONSORS

ICO would like to thank our sponsors:

abbvie

Alimera Sciences

Alcon

Allergan

Bayer

Braemar Finance

Challenge Insurances

Daybreak Medical

Eurosurgical

Haag Streit

Hospital Services

John Bannon

KD Surgical

Med Surgical

Merz Pharma

Novartis

Ocuco

Pamex

Pfizer

Rayner

Santen

Scope Ophthalmics

Sigmacon

Topcon

TP Whelehan

WMO Healthcare

Irish College of Ophthalmologists 1991 – 2016

25 Years Protecting Eye Health in Ireland

The ICO extends a warm welcome to you all to our annual conference. This year marks a special occasion for the ICO as we celebrate our 25th anniversary as the recognised training and professional body for eye doctors in Ireland.

The last 25 years have been an exciting time in the specialty of ophthalmology, with significant advances in medical technology and treatments for patients, as well as the continuing groundbreaking research into cures and treatments for sight threatening conditions, with this fast pace of advancement set to continue. It is wonderful that patients can be reassured of significantly improved outcomes for the most common eye conditions when compared with two decades ago, and for those with more rare eye diseases.

Genetic discoveries have leapt forward in the last 5 years with some of the first genetic treatments and stem cell treatments in medicine being carried out in the specialty of ophthalmology in conditions such as Lebers congenital amaurosis and retinitis pigmentosa. Anti-VEGF Injections have revolutionised the treatment of both age-related macular degeneration and diabetic eye disease and can stabilise the condition in 90% of cases, improve sight in 70% of cases and restore driving vision in 40%, if treatment is commenced promptly.

Macular degeneration is one of the major fields of ophthalmic research in Ireland, with on-going work aimed at targeting the inflammation and immune system that are part of macular degeneration. Following five years of work on the project, the research team at Trinity College Dublin hope to have a human study looking at treatment of inflammation as part of the management of Wet AMD in the next 12-18 months.

In 2010, the first radiotherapy implant treatment for uveal melanoma patients in Ireland was carried out by a team at the Royal Victoria Eye and Ear Hospital in Dublin. A fully dedicated Ocular Oncology Service is in operation at the Eye and Ear Hospital since 2010, in collaboration with treatment services at St Luke's Hospital, St Vincent's Hospital and the Royal Liverpool University Hospital. Initial assessment and diagnosis of patients takes place at the Eye and Ear Hospital, where the appropriate follow on location for treatment is determined. Between 2010 and 2015, 253 patients have been assessed at the Ocular Oncology Clinic.

The restoration of patient Jenny O'Connell's sight after 46 years of blindness when she was fitted with a Boston Keratoprosthesis, an artificial cornea for patients unsuitable for a corneal transplant, was another milestone.

Cataract surgery is today one of the most frequently performed procedures in Ireland, with over 95% of patients who undergo cataract surgery having excellent results. A typical cataract procedure twenty years ago would have involved an in-patient stay with significant after care. It is now a keyhole, day case procedure, utilising a very small incision of only 2.2mm. The expanding ageing population has led to an increasing demand for cataract surgery and the move to day case procedure and local anaesthetic rather than general, has made it an easier operation for patients to recover from.

Refractive laser surgery is one of the most rapidly evolving areas in ophthalmology and has seen significant advances in the last 25 years. Laser delivery, corneal flap construction and clear lens extraction are but a few areas that have improved so that refractive surgery is no longer limited to mild to moderate myopes but can also be suitable, for high myopes, hyperopes and patients with astigmatism.

More than 153,000 screenings of diabetic patients have been done under the National Diabetic Retinal Screening Programme, since the programme commenced in 2013. The programme has been an important development and ensures that diabetic patients with potential sight threatening retinopathies are identified and treated.

Continued investment in cost-effective interventions such as the DiabeticRetina Screen programme is essential to ensure eye diseases which are treatable, are detected early and unnecessary sight loss prevented. Since the introduction of the Diabetic Retina Screening programme in the UK, the eye disease is no longer the leading cause of blindness in the working age population in England.

Many remarkable and innovative new therapies are continuing to be realised in the speciality. Patients with the rare blinding disease limbal stem cell deficiency will soon have the option of a transplant in Ireland, and preparations are being made for the first transplantation operation aimed at restoring vision in patients with damaged or diseased cornea as a result of the deficiency.

There is, however, little doubt that the speciality is faced with many challenges as we strive to ensure that the best outcome for patients can prevail. The ICO must continue to be an authoritative figure in informing decisions in relation to the most appropriate care pathway for eye care patients and is committed to this role.

It is inevitable that the delivery of eye care in Ireland must continue to evolve in order to adapt to a myriad of influencing factors. Our ageing population, coupled with the medical advances made over the past two decades is resulting in an ever increasing demand for eye care services and resource issues urgently need to be tackled.

Quality of life expectations have also changed dramatically in the past 25 years, with a greater need than ever before for our senior citizens to maintain their independence and mobility. There is greater motivation for people to maintain their vision through the latest treatments accessible to them.

It is also an exciting time for trainees to be entering the speciality, as we look to the future delivery of eye care and the subsequent modifications to the model of training for eye.

Postgraduate Training in Ophthalmology in Ireland has evolved through many changes since the ICO was founded in 1991 and none more so than in the last decade. Challenged with integrating reforms new to all postgraduate training bodies in Ireland but adapting them to the particular needs of ophthalmology, the ICO has successfully forged its own speciality appropriate path in postgraduate education.

A major change has been the purposeful incorporation of competence-based education to both the medical and surgical curricula. Competence-based training brings a transparency and clarity to the training pathway which is key to attracting and retaining high-quality trainees.

A key feature of the new training pathway is that career progression and entry into medical or surgical ophthalmology is linked to trainee performance during the common core years of training. Equity of access to training opportunities across all training units for all trainees is essential.

The need to more effectively align training programs to future manpower demand and patient need has put the spotlight firmly on medical ophthalmology. The anticipated five-fold increase in the elderly population by 2040 as well as the unprecedented explosion of effective treatments in medical retina have fundamentally changed the way in which medical ophthalmology needs to be organised and practiced. Developments will continue to be incorporated into training to reflect these external factors. Many challenges lie ahead but despite some uncertainties the ophthalmic community – trainers, trainees and the College – will work together to ensure the continued delivery of high-quality ophthalmic training in the College and at all training sites nationally. The College will continue to collaborate with the HSE and the Medical Council on the enhancement of training.

The College is committed to ensuring that the high standards of ophthalmic training are maintained and to supporting the long term career prospects and opportunities for our excellent trainees. While continuing the focus on training, the College will also continue to advocate to decision makers to ensure that the numbers of doctors required to deliver the service that the public expects and deserves, are appointed.

The Clinical Programme for Ophthalmology presents an important opportunity to ensure that the model of delivery of eye care is appropriate for the Irish health service. The College supports the continuing work of the Programme and looks forward to the publication of the results of the HSE review of Primary Eye Care Services.

The ICO is committed to its patient advocacy role, including working with the National Vision Coalition to support calls for availability of services and with relevant decision makers on securing support for responsible advertising of medical and surgical services. The publication of Refractive Surgery Guidelines and Advertising and Marketing Guidelines in 2015, along with the Medical Advertising in Ireland Report in January 2016, have been important public statements of our expertise on patient safety matters.

An important focus for the future is on prevention and the importance of early detection. The ICO will continue to educate the public on eye health, highlighting the modifiable risk factors as well as the strong link between good eye health and overall health and wellbeing. Increased public awareness of the association of many general systemic conditions which affect eye health, including diabetes, sleep apnoea, various tumours, hypertension, sickle cell disease, lupus, and many others must also be a focus.

The ICO would like to sincerely thank our speakers, guests and all in attendance at this year's conference for your valued contribution and in ensuring it is a most successful, informative and enjoyable meeting.

PROGRAMME

Wednesday 18th May

9.00am Welcome

Mr William Power
President, Irish College of Ophthalmologists

9.05am Paper Session

Co-Chairs: Mr Tom Flynn and Dr Alison Blake

Outcomes in Deep Anterior Lamellar Keratoplasty (DALK) for Corneal Ectasia
Emily Hughes

Visual and Functional Outcomes of the TECNIS Symphony Extended Range of Vision 1-Piece Intraocular Lens (IOL), Model ZXROO
Aine Ní Mhéalóid

Incidence and Causative Organisms of Infective Keratitis in a North Dublin Population Following Audit of Corneal Scraping Practice from 2009-2016
Melissa Murphy

Corneal Tomographic Results Following Accelerated vs. Conventional Protocols for Corneal Collagen Cross-Linking in a Paediatric Population with Keratoconus
Lina Kobayter

Evidence Based Guidelines for the Management of Fungal Keratitis in the Republic of Ireland
Stephen Farrell

Audit of Indications, Complications and Surgical Outcomes Following Anterior Lamellar Keratoplasty (ALK) and Deep Anterior Lamellar Keratoplasty (DALK) in a Tertiary Referral Hospital
Melissa Murphy

Questions

10am Annual General Meeting

Chair: Mr William Power, President ICO

11.00am Coffee

11.30am The Eyes of Rebellion - Ophthalmology and Fighting for Freedom

Mr Tim Horgan
Consultant Ophthalmologist, University Hospital Kerry

12.00pm The Ins and Outs of Ocular Trauma

Chair: Ms Rizwana Khan

Eyelid and Orbital Trauma, Dodging the Stings and Arrows

Mr Dan Nolan
Consultant Ophthalmic Surgeon and Clinical Lead in Ophthalmology, East Cheshire NHS Trust Hospitals

Ocular Trauma and the Posterior Segment

Mr Paul Connell
Consultant Ophthalmic Surgeon, Mater Misericordia University Hospital, Dublin

1.00pm Lunch

2.00pm Paper Session

Co-Chairs: Mr David Keegan and Dr Geraldine Comer

Design of Nanoparticle-based MicroRNA Therapeutics in Sjögren's Syndrome

Sinead Connolly

Regulation of Lysyl Oxidase Like 1 expression in Pseudoexfoliation Glaucoma

Deborah Wallace

Significance of Novel RS1 Mutations in X-linked Retinoschisis

Kirk Stephenson

PROGRAMME

Target 5000: Next-generation Sequencing for Inherited Retinal Disorders

Matthew Carrigan

Negative Regulators of Inflammation and Age Related Macular Degeneration (AMD) in an Irish Population

Meadhbh Rhatigan

The role of AMD-derived exosomes in Age-Related Macular degeneration pathogenesis

Hanan El Shelmania

Questions

Evaluation of Tablet Computers in the Assessment of Visual Acuity: Can iPads Replace the Snellen Chart?

Conor Malone

3.00pm Technology and the Future of Healthcare

Mr Jim Joyce

Health-tech entrepreneur and Founder of Point of Care Clinic

3.30pm Coffee

4.00pm European Society of Ophthalmology (SOE) Lecture

Introduction by Ms Patricia Logan,
SOE Board Member

Tackling Immunological Events in Corneal Transplantation

Professor Conor Murphy

Consultant Ophthalmic Surgeon, Royal Victoria Eye and Ear Hospital, Dublin

4.30pm RetinaScreen Update

Mr David Keegan

National Clinical Lead Diabetic Retina Screen Programme, National Screening Service, Dublin

The impact of the Introduction of the Diabetic Retinal Screening (DRS) Programme on the Number of Laser Treatments Carried Out in the Ophthalmology Dept in UHG over a one-year period

Esraa Hegazy

Diabetic Retina Screen: The University Hospital Waterford Experience

Pathma Ramasamy

Thursday 19th May

9.00am Paper Session

Co-Chairs:

Miss Marie Hickey Dwyer and Dr Fiona Harney

Prism Adaptation and the Surgical Management of Acquired Esotropia

Clare Quigley

Cataract Surgery in Paediatric Uveitis

Michael O'Rourke

Questions

Objective Change in Metamorphopsia as Measured by an M-chart Following Epiretinal Membrane Surgery in Eyes with Good Visual Acuity

Iryna Surzhenko

The Differences between Retinoschisis and Retinal Detachments on Wide-Field Fundus Autofluorescence

Iryna Surzhenko

Uveal Melanoma: The Irish Experience

Caroline Bailey

Questions

PROGRAMME

Evaluation of Outcomes from Transsclear Cyclodiode Laser, in a Tertiary Referral Centre, Including the Outcomes in Neovascular Glaucoma in the Era of anti-VEGF

Shane Whitlow

Vision and Health-Related Quality of Life in Patients with Giant Cell Arteritis

Aine Ní Mhéalóid

10.00am Future of Specialist Training in Ireland

Introduction: Ms Yvonne Delaney,
Dean of Postgraduate Education, ICO

20 years of Ophthalmic Surgical Training Opportunities: 1995 to 2015 – What Has Changed?

Niamh Collins

Keynote Talk

Prof. Eilis McGovern
Director, National Doctors Training and Planning Health Service Executive

11.00am Coffee

11.30am Eye Care for Haiti

Dr Kevin Tempany
Ophthalmologist, Ranelagh Eye Clinic, Dublin

11.40am Vascular Symposium - Ocular Manifestations of Systemic Disease

Chair: Ms Patricia Logan

Ocular Manifestations of Cardiac Disease, the Common, the Complex and the Curious

Dr Charles McCreery
Cardiologist, St Vincents Hospital, St Colmcilles Hospital and Blackrock Clinic, Dublin

Imaging in Neuro-ophthalmology: What to Order and How to Maximise your Diagnostic Yield

Dr Ronan Killeen
Consultant Diagnostic Neuro-radiologist & Nuclear Medicine Physician, St Vincent's University Hospital and Royal Victoria Eye and Ear Hospital, Dublin

Update in Neurology

Dr Brian Sweeney
Consultant Neurologist, Cork University Hospital, Cork

Questions

1.00pm Lunch

2.00pm Workshops (running concurrently)

1. The Future Development of Medical Ophthalmology - the Great Debate

Chair: Dr Fiona Kearns,
Chair Medical Ophthalmologists Committee, ICO

2. Trainee Workshop:

Chair: Mr Jeremy O Connor,
Chair Scientific & CME Committee, ICO

Applying for a fellowship and early career advice

Delivering difficult news – Insight Counselling, Fighting Blindness

3.00pm Practical Diagnostic Corneal Imaging

Mr Tom Flynn,
Consultant Ophthalmic Surgeon, Moorfields Hospital, London

PROGRAMME

Friday 20th May

9.00am

Poster Session

Chair: Dr Denise Curtin

Accuracy of Glaucoma Drops Prescribing and Dispensing for Patients Admitted to Hospital for Non-Ophthalmic Complaints

Mohamad Baba

Implementing a Retinal Artery Occlusion and Retinal Vein Occlusion protocol in an Acute Medical Unit

Esraa Hegazy

Trabeculectomy Outcomes: Do Results in a District General Hospital Setting Compare to Larger Centres?

Aisling Higham

Case Series Report: Congenital Dural Ectasia of the Optic Nerve

Mohamad Hosney

Paediatric Ocular Cystinosis in the Republic of Ireland

Stephen Farrell

A1 Base – Pair Frameshift Deletion in Codon 893 of SLC24A1 Causes Retinitis Pigmentosa

Conor Malone

The Audit of Risk Factors and Clinical Features of Retinal Tears Diagnosed in Eye Casualty

Donal McCullagh

Ocular Immunoglobulin G4-related Disease. A Case Series

Elizabeth McElena

Initial Clinical Experience with the Trabecular Micro-Bypass Stent (iStent) in Patients with Open Angle Glaucoma

Sarah Moran

Eye Massage: Impact on Clinical Signs and Quality of Vision

Johnny Moore

Popper Associated Maculopathy – Case Report and Literary Synthesis

Rory Murphy

The Changing Treatment Profile of Diabetic Macular Oedema: The Decline of Macular Laser

Teasa Murphy

Workings of the Royal Victoria Eye and Ear Hospital Application for Smart Phones

Patrick Murtagh

Union is Strength: Looking Back on the First Year of the British Journal of Ophthalmology Founded 100 Years Ago

Shane O'Regan

A Retrospective Audit of the Epidemiology of Surgical Presentations to the UHW Vitreoretinal Unit

Barry Power

11.00am ANNUAL MOONEY LECTURE 2016 Regulation of Corneal Inflammation and Immunity

Dr Reza Dana

Claes Dohlman Professor of Ophthalmology, Harvard Medical School and Director of the Department of Ophthalmology Cornea Center of Excellence

11.00am Coffee

PROGRAMME

11.30pm **Evolving Trends in Corneal Disease**

Chair: Mr William Power

Update on ocular graft-versus-host disease

Dr Reza Dana

Professor of Ophthalmology, Harvard Medical School

Deep Anterior Lamella Keratoplasty (DALK)

Mr Tim Fulcher,

Consultant Ophthalmic Surgeon, Mater and Beaumont Hospitals, Dublin

Evolution of Endothelial Keratoplasty

Mr Tom Flynn,

Consultant Ophthalmic Surgeon, Moorfields Hospital, London

Changing Indications for Keratoprosthesis Surgery

Mr Billy Power

Consultant Ophthalmic Surgeon, Royal Victoria Eye and Ear Hospital, Dublin

1.00pm **Update from ICO / Novartis Bursary Recipients 2016**

Mitochondrial Respiratory Function and Mitochondrial DNA Mutations in Pseudoexfoliation Glaucoma

Dr. Khalid Kamel

Neutralising Interleukin-18 binding protein (IL-BP) as a potential therapy for treatment of neo-vascular AMD

Dr. Ghaleb Farouki

Announcement of ICO Medal Winners

MOONEY LECTURER 2016

Dr Reza Dana



Reza Dana, MD, MPH,
MSc, FARVO

Dr Reza Dana, MD, MPH, MSc, FARVO

**Claes H. Dohlman Professor of Ophthalmology,
Harvard Medical School**

Vice Chair for Harvard Department of Ophthalmology

Director, Harvard-Vision Clinical Scientist Development Program

Director, Cornea Service, Mass. Eye and Ear

**Senior Scientist, Mass. Eye and Ear/Schepens Eye Research Institute
Committee on Immunology, Harvard Medical School**

Prof. Reza Dana holds the Claes Dohlman Chair in Ophthalmology at Harvard Medical School and is Senior Scientist & W. Clement Stone Scholar at the Schepens Eye Research Institute, Mass Eye and Ear, as well as the Director of Cornea & Refractive Surgery, Massachusetts Eye & Ear, and Vice Chairman of Harvard Department of Ophthalmology.

Dr. Dana completed his bachelor's, graduate, and medical education at Johns Hopkins and performed his residency at the Illinois Eye and Ear Infirmary, followed by fellowships in Cornea and External Diseases at the Wills Eye Hospital, in Uveitis at the Massachusetts Eye and Ear, and in Ocular and Transplantation Immunology at Schepens Eye Research Institute, Harvard Medical School. In addition, Dr. Dana also holds a Masters in Health Care Management from Harvard University.

Areas of active research in Dr. Dana's research program include ocular surface autoimmunity, mechanisms of T cell activation and regulation in transplantation, cytokine regulation of leukocyte trafficking, corneal angiogenesis, novel immunomodulatory strategies in ocular inflammation, and development of bioengineered stromal constructs.

Dr. Dana is a 'Gold Fellow' of the Association for Research in Vision and Ophthalmology (ARVO) and has authored over 240 peer-reviewed articles and over 120 reviews and book chapters, and has delivered more than 200 invited and named lectures worldwide. His citation index (h-factor) is 65 and his work has been cited more than 15,000 times in the published literature.

He has been the recipient of multiple awards, including the Special Scholar Award, Physician-Scientist Award, Lew R. Wasserman Award,

MOONEY LECTURER 2016

Dr Reza Dana

and the Senior Scientific Investigator Award from Research to Prevent Blindness, the Cogan Award from ARVO, the LSU Chancellor's Award in Neuroscience and Ophthalmology, the Thygeson Lectureship, the Alcon Research Institute Award, the Kersley Medal (UK), the Endre A. Balazs Prize from ISER, and the Mooney Lectureship among many others. In 2014, he was the recipient of the A. Clifford Barger Excellence in Mentoring Award at Harvard Medical School. Dr. Dana is Associate Editor of IOVS, and is on the editorial board of Cornea, Scientific Reports, Ocular Surface, and UpToDate Rheumatology and Senior Editor of Encyclopedia of the Eye.

In addition to his basic laboratory investigations, Dr. Dana leads a sizeable translational research program at Mass. Eye and Ear that has received 9 IND permits from the FDA in the last few years. These 'lab-to-clinic' studies have focused on novel strategies to manage high-risk corneal transplants, pathological corneal angiogenesis, dry eye, graft-versus-host disease, and in vivo corneal immuno- and neuro-imaging. Apart from Dr. Dana's many clinical trainees, he has trained over 100 post-doctoral fellows, students, and scientists from 30 countries in his laboratory to date. His research has received continuous funding from the NIH since 1995, and is currently supported (as PI) by 2 RO1 and 1 DOD grants, in addition to his serving as PI on HMS Ophthalmology's NIH K12 Clinical Scientist Development Program.

BIOGRAPHIES



Mr Dan Nolan

Mr Dan Nolan

Consultant Ophthalmic Surgeon and Clinical Lead in Ophthalmology, East Cheshire NHS Trust Hospitals

Mr Dan Nolan qualified at University College Hospital Galway in 1994 and continued his Ophthalmology training in Glasgow and Manchester, completing his fellowship in Oculo Plastic, Orbital and Adnexal Surgery. He is an examiner for the Royal College of Ophthalmologists and external examiner for University College London. Having been a consultant at the Royal Oldham Hospital since 2005, Dan was appointed as a Consultant at Manchester Royal Eye Hospital in 2012 and subsequently to East Cheshire NHS Trust Hospitals in 2015, where he is now the Clinical Lead. He is a founding partner of Manchester Consultants Eye Partnership.



Charles McCreery

Dr Charles McCreery

Cardiologist, St Vincents Hospital, St Colmcilles Hospital and Blackrock Clinic, Dublin

Dr Charles McCreery, FACC, FRCPI, graduated from UCD in 1986. He undertook basic medical and cardiology training in Ireland before doing residency and cardiology fellowship in Pittsburgh and Baylor College of Medicine in Houston Texas. He joined the faculty at the University of Texas in Galveston in 1997 and became the director of the coronary care unit. He returned to Houston at the DeBakey Heart Institute in 2000 before coming back to Ireland in 2002. He is an interventional cardiologist at St Vincents Hospital, St Colmcilles Hospital and Blackrock clinic.



Dr Ronan Killeen

Dr Ronan Killeen

Consultant Diagnostic Neuro-radiologist & Nuclear Medicine Physician, St Vincent's University Hospital and Royal Victoria Eye and Ear Hospital, Dublin

Dr Ronan Killeen is a radiologist working within St Vincent's Healthcare Group and is the lead Consultant Radiologist in The Royal Victoria Eye and Ear Hospital in Dublin. He did his fellowship training in New York Presbyterian Hospital in Neuroradiology and Molecular imaging and subsequently was board certified as a nuclear medicine physician. He has published more than 30 papers, written several book chapters and authored a book on the use of PET CT in Oncology.

His particular interests are in multimodality imaging of neurological disease including demyelination, head and neck cancer and orbital disease in addition to molecular imaging in dementia and movement disorders.

BIOGRAPHIES



Dr Brian Sweeney

Dr Brian Sweeney

Consultant Neurologist, Cork University Hospital

Dr Brian Sweeney has been a consultant neurologist at Cork University Hospital since 1996. He graduated from UCD in 1986. He trained in neurology in Cork and in London at the Middlesex and University College Hospitals, the National Hospital for Neurology and Neurosurgery, Queen Square, St Mary's Hospital, Paddington, and the Western Eye Hospital.

He has clinical and research interests in multiple sclerosis, headache, epilepsy and movement disorders.



Mr Tom Flynn

Mr Tom Flynn

Consultant Ophthalmic Surgeon, Moorfields Hospital, London

Tom Flynn has been a Consultant Ophthalmic Surgeon at Moorfields Eye Hospital NHS Foundation Trust in London since 2013 where he specialises in cornea, external disease and cataract surgery. A graduate of University College Cork, he completed basic specialist training in ophthalmology in Cork before moving to London to complete a three year research fellowship at Moorfields Eye Hospital and The UCL Institute of Ophthalmology. He was awarded a PhD by University College London for his research on corneal transplant immunology. He undertook higher specialist training in ophthalmology in London and spent a further two years in clinical fellowship training in cornea and external disease at Moorfields Eye Hospital. His areas of special interest include corneal transplantation, allergic eye disease, keratoconus and complex cataract surgery. He lives in West London with his wife and two children.



Prof. Eilis McGovern

Professor Eilis McGovern

Director, National Doctors Training and Planning, HSE

Professor Eilis McGovern, FRSCI, is the Director of the National Doctors Training and Planning unit (NDTP) in the Health Service Executive. In 2012, Prof. McGovern replaced the previous Director of Medical Education & Training (MET), Prof. Gerard Bury.

NDTP is responsible for overseeing the HSE's legislative responsibilities and policy development for medical education and training, as well as medical workforce planning and consultant post approval.

ANNUAL MONTGOMERY LECTURER 2015

A graduate of University College Dublin Medical School in 1978, Prof. McGovern completed internship and basic surgical training before obtaining her Fellowship of the Royal College of Surgeons in Ireland in 1982. She then trained in cardiothoracic surgery in Dublin, followed by a clinical fellowship in the Mayo Clinic, Rochester, Minnesota.

She was appointed as a consultant cardiothoracic surgeon to the Mater and Royal City of Dublin Hospitals in 1987. In 1999, she transferred to St James's Hospital in Dublin to oversee the opening of a new cardiac surgery unit.

In the field of undergraduate medicine, she chaired the Medical Faculty Board of the Royal College of Surgeons medical school from 2001 until 2006. She has a long track record in postgraduate training and is a past member of the Intercollegiate Board for cardiothoracic surgery (UK and Ireland) and a former examiner. She chaired the Irish Postgraduate Medical and Dental Board from 2003 to 2007, which was the precursor of NDTP. She currently chairs a Ministerial policy group tasked with developing a trauma system for the Irish health service.

Professor McGovern was President of the Royal College of Surgeons in Ireland, from 2010 to 2012, having been a Council Member since 1993.



Mr Jim Joyce

Mr Jim Joyce

Health-tech entrepreneur and Founder of Point of Care Clinic

Jim Joyce is a Dublin based healthcare entrepreneur who is Chairman/Co-Founder of medical adherence company, HealthBeacon.

Jim founded award winning healthcare services company Point of Care Health delivering medical infusions in Ireland and the UK. Prior to this, he worked for over 10 years in the pharmaceutical industry including Managing Director and founding executive of Schering Plough's Irish country operations.

His past roles in pharmaceuticals include Director of USA Finance, Director of Europe/Mid East/Canada and has experience working in both Primary Care and Specialty Biotech Product Lines.



Irish College of
Ophthalmologists
Eye Doctors of Ireland
Protecting your Vision

Irish College of Ophthalmologists

121 St Stephen's Green, Dublin 2
Telephone 01 402 2777

Web: www.eyedoctors.ie · Email: info@eyedoctors.ie

📱: [@eyedoctorsirl](https://www.instagram.com/eyedoctorsirl)